Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 10/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15813634 | 0.93 | GPR84 (0.40) | PLA2G7GPR84PDE4AKDM4EALDH1A1 | |
| SCHEMBL14656420 | 0.90 | GPR84 (0.36) | PLA2G7GPR84PDE4A | |
| SCHEMBL14656083 | 0.89 | GPR84 (0.44) | PLA2G7GPR84PDE4AKDM4EMAPK1 | |
| SCHEMBL14656354 | 0.89 | PLA2G7 (0.42) | PLA2G7GPR84PDE4A | |
| SCHEMBL14656309 | 0.89 | MAOA (0.45) | GPR84KDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL14656298 | 0.89 | PLA2G7 (0.49) | PLA2G7GPR84 | |
| SCHEMBL14667659 | 0.88 | PLA2G7 (0.42) | PLA2G7GPR84PDE4A | |
| SCHEMBL15829146 | 0.85 | PLA2G7 (0.40) | PLA2G7GPR84PDE4A | |
| SCHEMBL14656096 | 0.85 | PLA2G7 (0.41) | PLA2G7GPR84PDE4A | |
| SCHEMBL14670086 | 0.85 | GPR84 (0.37) | PLA2G7GPR84PDE4AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | PLA2G7 1/4885GPR84 911/4885PDE4A 260/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | PLA2G7 2/4885GPR84 847/4885PDE4A 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.